Archive: 17/09/2012

Tafamidis: Approval denotes proven added benefit

Tafamidis meglumine (trade name: Vyndaqel) was approved in November 2011 for the treatment of transthyretin amyloidosis in adults. This rare disorder ("orphan disease") is caused by a defective gene and is associated with ...

Report: Cancer now leading cause of death in US hispanics

A new report from American Cancer Society researchers finds that despite declining death rates, cancer has surpassed heart disease as the leading cause of death among Hispanics in the U.S. In 2009, the most recent year for ...

page 5 from 9